Mabpharm Limited Stock

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 16:08:15 02/11/2026 HKT			5-day change	1st Jan Change
0.4300 ^HKD	-1.15%		-6.52%	-14.00%

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

394

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/11/26	HK$0.4300	-1.15%	22,000
30/10/26	HK$0.4350	0.00%	0
29/10/26	HK$0.4350	0.00%	72,000
28/10/26	HK$0.4350	0.00%	0
27/10/26	HK$0.4350	-1.14%	102,000

Delayed Quote Hong Kong S.E.

More quotes

Market Cap	1.5B 1.77B 226M 202M 185M 168M 316M 21.4B 322M 2.21B 892M 11.29B 848M 830M 35.67B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.72B 2.03B 259M 231M 212M 193M 361M 24.49B 369M 2.53B 1.02B 12.93B 971M 950M 40.83B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

1 day	-1.15%
1 week	-6.52%
Current month	-1.15%
1 month	-4.44%
3 months	+7.50%
6 months	-3.37%
Current year	-14.00%

1 week	0.42	0.44
1 month	0.42	0.55
Current year	0.31	0.81
1 year	0.31	0.81
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news: Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Price Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	-1.15%	-6.52%	-17.31%	-8.51%	229M
WUXI APPTEC CO., LTD.	-2.37%	-4.19%	+39.49%	+63.21%	63.77B
ARGENX SE	-2.87%	+0.23%	+11.11%	+68.89%	56.37B
LONZA GROUP AG	+0.62%	+2.60%	+16.96%	+103.45%	54.62B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+20.83%	+35.69%	44.06B
BEONE MEDICINES AG	-2.45%	-2.59%	+15.84%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+217.16%	+789.69%	41B
GENMAB A/S	-5.47%	+39.86%	+101.20%	+80.57%	34.92B
CELLTRION, INC.	+0.21%	-1.23%	+14.81%	+47.35%	32.82B
INSMED INCORPORATED	-2.90%	+17.12%	-41.30%	+337.07%	24.7B
Average	-2.04%	+6.41%	+37.88%	+161.59%	39.46B
Weighted average by Cap.	-2.06%	+5.63%	+44.49%	+163.10%

	2024	2025
Net sales	258M 305M 38.83M 34.66M 31.81M 28.94M 54.25M 3.68B 55.33M 380M 153M 1.94B 146M 143M 6.13B	646M 762M 97.15M 86.73M 79.59M 72.4M 136M 9.2B 138M 951M 383M 4.85B 365M 357M 15.33B
Net income	-128M -151M -19.24M -17.18M -15.76M -14.34M -26.88M -1.82B -27.42M -188M -75.88M -961M -72.2M -70.66M -3.04B	57.13M 67.4M 8.59M 7.67M 7.04M 6.4M 12M 813M 12.24M 84.06M 33.89M 429M 32.24M 31.55M 1.36B
Net Debt	222M 262M 33.42M 29.83M 27.38M 24.9M 46.69M 3.16B 47.62M 327M 132M 1.67B 125M 123M 5.27B	217M 257M 32.7M 29.19M 26.79M 24.37M 45.69M 3.1B 46.6M 320M 129M 1.63B 123M 120M 5.16B